Streetbeat News

Analyst Ratings

AMD

LLY

NVDA

DataTrek's analysis suggests that mega-cap stocks like Nvidia (NVDA), Eli Lilly (LLY), and AMD (AMD) may withstand the current higher rate environment despite their high P/E ratios. Historical context shows that while the Fed's aggressive rate cycle in 2022 and 2023 has raised concerns, it has not impacted equity valuations as significantly as the volatility seen in the 1970s. The firm notes that the current debate over the Fed funds rate is less severe compared to past decades, and even if rates were to increase significantly, it might not affect equity valuations as much as expected.

Portfolio Pulse from Neil Dennis

February 27, 2024 | 8:35 pm

GRMN

Tigress Financial analyst Ivan Feinseth has reiterated a Strong Buy rating on Garmin (NYSE:GRMN) and increased the price target from $165 to $175.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 8:34 pm

WRB

WR Berkley (NYSE:WRB) has received diverse analyst ratings over the last three months, with a recent shift towards a more neutral stance. The average 12-month price target for WRB has increased to $84.11, reflecting an 8.53% rise from the previous target of $77.50. Analysts from firms including Keefe, Bruyette & Woods, UBS, BMO Capital, Truist Securities, Wells Fargo, RBC Capital, and Evercore ISI Group have raised their price targets, indicating a positive outlook on the company's performance. WR Berkley, an insurance holding company, has shown solid revenue growth but faces challenges in profitability, efficient use of equity and assets, and debt management.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 8:00 pm

FATE

Fate Therapeutics (NASDAQ:FATE) received mixed analyst ratings in the latest quarter, with an average 12-month price target of $7.75, indicating a significant increase from the previous $4.50. Analysts from Morgan Stanley, BMO Capital, Barclays, and Wedbush raised their price targets, reflecting a positive outlook on the company's performance. Despite a substantial decline in revenue growth (-87.02%) and challenges in ROA, Fate Therapeutics shows strong profitability with a high net margin (-2323.56%) and effective use of equity capital as evidenced by its ROE (-10.75%).

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 8:00 pm

CCO

Barrington Research analyst James Goss has reiterated an Outperform rating on Clear Channel Outdoor (NYSE:CCO) and maintained a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 7:49 pm

ESPR

Needham analyst Serge Belanger has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 7:47 pm

SNOW

Piper Sandler analyst Brent Bracelin has reiterated an Overweight rating on Snowflake (NYSE:SNOW) and maintained a $250 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 7:45 pm

PAR

Needham analyst Mayank Tandon has reiterated a Buy rating on PAR Technology (NYSE:PAR) and increased the price target from $47 to $53.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 7:43 pm

TMDX

TransMedics Group Inc (NASDAQ:TMDX) reported a Q4 profit with revenue of $81.2 million, up 159% Y/Y, surpassing the consensus of $68.51 million. The growth was attributed to increased use of its Organ Care System (OCS) and new logistics services. EPS was $0.12, beating the expected loss of $(0.03). The company expects FY 2024 revenues of $360-$370 million, above the consensus of $330.23 million. Oppenheimer raised TMDX's price target from $92 to $105 with an Outperform rating, and William Blair maintains an Outperform rating, highlighting the company's strong Q4 results and promising outlook.

Portfolio Pulse from Vandana Singh

February 27, 2024 | 7:33 pm

DHR

VLTO

BMO Capital Markets analyst John P. McNulty initiated coverage on Veralto Corporation (VLTO) with an Outperform rating and a price target of $97, citing strong EPS growth potential in the next 2-3 years. Veralto, which spun off from Danaher Corp (DHR) and began NYSE trading in October 2023, is expected to leverage its high-margin businesses and significant free cash flow for M&A to support double-digit EPS growth. The company recently reported Q4 earnings that beat consensus estimates and anticipates flat Y/Y non-GAAP core sales for Q1 FY24 with adjusted EPS of $0.73-$0.78.

Portfolio Pulse from Lekha Gupta

February 27, 2024 | 7:15 pm